Unitaid has welcomed Gilead’s announcement of royalty-free voluntary licensing agreements with Dr. Reddy’s Laboratories, Eva Pharma, and Ferozsons Laboratories. The agreements establish the foundation for broader access to obeldesivir, an investigational antiviral currently being studied as a means of preventing Ebola Bundibugyo virus disease (BVD). Should clinical evidence support its use and regulators grant approval, the three manufacturers, spanning multiple regions, will be positioned to produce and supply obeldesivir across the 127 countries covered by the licenses.
Gilead is further extending its existing licenses for remdesivir, an antiviral used to treat COVID-19, to include Ebola BVD. This expansion opens a path toward wider access, pending the outcome of ongoing clinical trials.
Although clinical trials remain in progress, Unitaid, the World Health Organization, affected countries, and regional and international partners engaged in the Ebola response have already developed access roadmaps for candidate BVD medicines, including obeldesivir and remdesivir. These roadmaps outline the steps stakeholders can take now to help countries secure supplies rapidly should the medicines prove effective. As part of this effort, Unitaid is leading engagement with the manufacturers of both antivirals to secure commitments to supply all countries in need. Through its funded programs, Unitaid is also supporting and preparing interventions to ready the supply and adoption of therapeutics and diagnostics, enabling countries to introduce these critical tools without delay if trial results support their use.

